Issued: 29 February 2024, London
UK
GSK
announces Dr Jeannie Lee to join the Board as Non-Executive
Director
GSK plc (LSE/NYSE: GSK) has today
announced that Dr Jeannie Lee has been appointed to the Board of
the Company as a Non-Executive Director. Jeannie will join the
Board on 4 March 2024.
Jeannie is currently the Phillip A.
Sharp, PhD, Endowed Chair in Molecular Biology and Acting Chair of
the Department of Molecular Biology at the Massachusetts General
Hospital. She is also Professor of Genetics (and Pathology) at
Harvard Medical School. She is a pioneer in the field of RNA
Biology and its application to drug development and therapeutics.
In addition to senior leadership positions held at both Harvard
Medical School and the Massachusetts General Hospital, Jeannie
co-founded Translate Bio and Fulcrum Therapeutics, two biotech
companies specialising in RNA and epigenetic therapies.
Jeannie is a Member of the National
Academy of Sciences, the National Academy of Medicine, a Harrington
Rare Disease Scholar of the Harrington Discovery Institute, a
recipient of the Lurie Prize from the Foundation for the National
Institutes of Health, an awardee of the Centennial Prize from the
Genetics Society of America, the 2010 Molecular Biology Prize and
the 2020 Cozzarelli Prize from the National Academy of Sciences,
U.S.A, and a Fellow of the American Association for the Advancement
of Science. She has also served on the Board of the Genetics
Society of America.
Commenting on the appointment, Sir Jonathan Symonds, Chair of
GSK said, "I am delighted to welcome
Jeannie to GSK. Her deep expertise in scientific and medical
innovation, including in the field of RNA biology and epigenetics
which are key parts of GSK's R&D approach, together with her
experience in public health, will bring strong additional
perspective to the Board."
Notes:
|
|
1. The appointment of Dr
Lee was made by the Board on the recommendation of the Nominations
& Corporate Governance Committee. The Committee conducted an
extensive search and selection process for this appointment, using
an external search firm, which is a signatory of the Voluntary Code
of Conduct for Executive Search Firms. The external search firm
provided a diverse list of candidates who were approached,
evaluated and interviewed against an agreed set of criteria aligned
to the Board's target skills matrix. The Board satisfied itself
that Dr Lee had the experience and time available to carry out the
role.
|
|
|
2. The Board has
determined that Dr Lee is an independent Non-Executive Director in
accordance with the UK Corporate Governance Code.
|
|
|
3. Dr Lee will receive
the standard basic fee for a Non-Executive Director of £118,352 per
annum (including travel allowance). She will also receive fees of
£30,000 per annum as a scientific and medical expert. Dr Lee will
be required to build towards a share ownership requirement of GSK
shares in accordance with the Company's shareholder approved
Non-Executive remuneration policy.
|
|
|
4. "Scientific and
Medical Expert" - The Board designates Non-Executive Directors
whose expertise or backgrounds as renowned medical scientists,
researchers, or physicians mean that they can bring scientific or
industry expertise to the Board's deliberations.
|
|
|
5. Dr Lee will become a
member of the Science and Corporate Responsibility committees on
her appointment.
|
|
|
6. Dr Lee does not have
a service contract. She has a letter of appointment which may be
viewed by contacting the Company Secretary at the Company's
registered office.
|
|
|
7. There are no further
disclosures to be made in respect of Dr Lee's appointment under
Listing Rule 9.6.13R.
|
|
|
8. As of 4 March 2024,
the Board of GSK will comprise:
|
Sir Jonathan Symonds
|
Non-Executive Chair
|
|
Emma Walmsley
|
Chief Executive Officer
|
|
Julie Brown
|
Chief Financial Officer
|
|
Charles Bancroft
|
Senior Independent Non-Executive
Director
|
|
Elizabeth McKee Anderson
|
Independent Non-Executive
Director
|
|
Dr Hal Barron
|
Non-Executive Director
|
|
Dr Anne Beal
|
Independent Non-Executive
Director
|
|
Wendy Becker
|
Independent Non-Executive
Director
|
|
Dr Hal Dietz
|
Independent Non-Executive
Director
|
|
Dr Jesse Goodman
|
Independent Non-Executive
Director
|
|
Dr Jeannie Lee
|
Independent Non-Executive
Director
|
|
Urs Rohner
|
Independent Non-Executive
Director
|
|
Dr Vishal Sikka
|
Independent Non-Executive
Director
|
|
About GSK
GSK is a global biopharma company
with a purpose to unite science, technology, and talent to get
ahead of disease together. Find out more at gsk.com.
|
GSK
enquiries
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
|
|
|
|
| |
Cautionary statement regarding forward-looking
statements
GSK cautions
investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to
risks and uncertainties that may cause actual results to differ
materially from those projected. Such factors include, but are not
limited to, those described under Item 3.D "Risk factors" in the
company's Annual Report on Form 20-F for 2022, and Q4 Results for
2023.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS